PARIS STARTUP SQUAREMIND RAISES $18M FOR AI SKIN IMAGING ROBOT

The funding includes backing from Sonder Capital, the venture firm founded by Fred Moll, a notable figure in medical robotics. SquareMind's Swan platform combines robotics with artificial intelligence to automate dermoscopic skin imaging across the entire body. The technology addresses a key challenge in dermatology: standardizing and scaling skin cancer screening while reducing manual labor and human error. Dermoscopic imaging allows clinicians to examine skin lesions at magnified levels to identify potential melanomas and other skin conditions. Automating this process with robotics could streamline workflows in dermatology clinics and hospitals. The $18 million raise signals growing investor interest in AI-powered medical robotics, particularly in areas where automation can enhance diagnostic accuracy and clinical efficiency. The funding will likely support further product development and commercial expansion for SquareMind's platform.